Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy - Wikidata - awgldk - TriplyDB

Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy

Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy

http://www.wikidata.org/entity/Q35207771

about

CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.Advances in the understanding of trauma-induced coagulopathy Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.Pathologic metabolism: an exploratory study of the plasma metabolome of critical injury Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage.Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid Early hemostatic responses to trauma identified with hierarchical clustering analysis.Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock.The "Death Diamond": Rapid thrombelastography identifies lethal hyperfibrinolysis.Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation.Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients.Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.Prehospital administration of tranexamic acid in trauma patients.Metabolomics of trauma-associated death: shared and fluid-specific features of human plasma vs lymph.The accumulation of lipids and proteins during red blood cell storage: the roles of leucoreduction and experimental filtration.Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis.The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.Coagulopathy and its management in patients with severe burns.Hemoglobin-based oxygen carriers promote systemic hyperfibrinolysis that is both dependent and independent of plasmin.Thrombelastography indicates limitations of animal models of trauma-induced coagulopathy.Viscoelastic Tissue Plasminogen Activator Challenge Predicts Massive Transfusion in 15 Minutes.β-Blockade use for Traumatic Injuries and Immunomodulation: A Review of Proposed Mechanisms and Clinical Evidence.Effectiveness of early administration of tranexamic acid in patients with severe trauma.Management of Trauma-Induced Coagulopathy with Thrombelastography.Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion.Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage.Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma.[Uncritical use of tranexamic acid in trauma patients : Do no further harm!][Early viscoelasticity-based coagulation therapy for severely injured bleeding patients: Report of the consensus group on the consensus conference 2014 for formulation of S2k guidelines].Fibrinolysis for intermediate-risk pulmonary embolism.Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.Adenosine, lidocaine and Mg2+ (ALM) fluid therapy attenuates systemic inflammation, platelet dysfunction and coagulopathy after non-compressible truncal hemorrhage.Fibrinolysis in trauma: a review.Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator.Targeting resuscitation to normalization of coagulating status: Hyper and hypocoagulability after severe injury are both associated with increased mortality.

P2860

Q26785966-1A7CC559-DA79-47C3-A2CA-AA55AB277518 Q28083939-C0B171E6-2B44-439F-AEC7-6AACD4725E47 Q29994525-16673376-1BF1-46CE-8998-A89B8826DE5D Q33676496-4FED412B-372A-43F8-BFB4-CC1698BA1743 Q34677754-D1E9C1CD-715A-4B6A-B9AB-91FF5475EE3C Q35216740-D78DA68B-FB58-4CB9-93A8-F98788BC85ED Q35222313-AFB31391-E777-402A-AF9D-FAE83FF27D5A Q35537165-BE04611B-0CBD-492B-B715-01C7A306993E Q35646892-25D70261-FF6A-4DD6-8942-C2ED04D4EF26 Q35674787-21DDB406-74A5-44BA-A94E-E519AB04819D Q35822899-30E261C7-F5CE-4D9E-9A22-05B6C3111C56 Q36387078-725B09CF-0D63-47A8-BCD4-D87C435E0A0F Q36390547-85EC80F2-CD78-453A-B39B-0EF7DAA137A9 Q36396010-3A0CDAB8-15E9-4874-B414-1F86FC6B146C Q36461468-0F67B049-D5A7-4305-BDC1-4FAE91413E73 Q36807586-E408154B-2FE3-4195-AFCF-C2DB4DC58C00 Q36818081-C9E79405-69E9-4831-9653-747F24791461 Q36898573-BE46FC0C-D832-404E-9746-903ED4F7EBC3 Q37032262-80CDFE00-C57F-41BF-9F1B-D0FF6024A382 Q37679818-FC03C3B6-DC51-4F2C-9C4C-B9CC3C083FDF Q38653755-611CF9CB-E680-4EBE-909F-AFBCE7830C4F Q38679752-6B3C50E7-9EB8-4189-872D-550268D1AF7A Q38725913-7CB77C13-23B4-4F3C-9DB9-F6C7F6052E5F Q38732501-CF022342-FAE9-43BE-8CAB-BB5CBF511CE8 Q38742341-6BAF88AA-76DA-4F20-AFFA-3B3996A01EC9 Q38776292-354716E6-8B59-4A16-A459-0F5DFD841216 Q38832894-6B821C83-679C-490B-8F89-D6CBD8E3AE74 Q38946580-2F85350C-34CE-4302-A7AF-B3C12A4F1120 Q39022502-3F9C3BF8-8FA6-42B6-92D1-182285075C1E Q39224083-755DA802-58E8-4BAA-BF3B-02B287AAB949 Q39364102-07C01655-9778-42C2-AEC8-A89BF856973E Q40153017-F5D380A9-D61F-40D4-BF0C-B4C58AD53C6C Q40577604-E2429B8E-3F2C-498F-BBA0-CDB80E3DBE4C Q41619894-69B58BD9-4864-488C-8A6F-AED5EBDC2B3C Q42686542-B6D17D0D-F077-41C2-A28D-2799BD859EF0 Q45375279-2E4AB523-EF2D-42C1-BFDC-28969D6E9B5D Q47117935-3716DD64-2FC8-4677-9A10-FB7FB5067DDF Q47251777-1D9883B4-85E8-485A-A6CF-50BF3578412F Q47347417-CDF1915B-A1B4-40BC-99F8-D4A4B92EFA0B Q47880955-ED51C28F-B7F8-4CCC-9B05-C123091E7B9D

P2860

Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy

http://www.wikidata.org/entity/Q35207771

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@ast

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@en

type

label

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@ast

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@en

prefLabel

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@ast

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@en

P1433

Q35207771-5629D868-2CB4-461F-BCD3-A2F9BD92F193

P1476

Q35207771-E6343343-85E2-4041-BAF2-D0560247F6CC

P2093

Q35207771-261F204F-6E77-4C2F-A3D7-615F58555412

Q35207771-2A3FBF3A-457D-45D5-BB6A-A67E870E37D9

Q35207771-3F1C4F95-77F4-4A85-B754-BA5161CD3272

Q35207771-4A6E86E4-BFBE-4B36-BCA0-752C6161B0AB

Q35207771-56659CAE-0B5A-463E-9791-C5606F5DAC2E

Q35207771-6FD5E1E4-988B-4D42-AD67-D90D1CBAD864

Q35207771-C5C7BA21-C14B-4578-A314-CE78043495B1

Q35207771-F99EADCC-C2D5-4C96-9866-3B14A6C70C48

P2860

Q35207771-04914825-35CD-4F8B-9381-E835749A0CB5

Q35207771-0A6AC1FD-2EA1-4E60-AA55-862C917D5662

Q35207771-16216B4C-86F4-4D48-ABC3-B4E7A6A5B8C1

Q35207771-1BD879AB-EC4A-4053-8B83-C64AEC4C3A6F

Q35207771-20378C5F-91A2-4D0E-AE8B-38DD84D39BA4

Q35207771-27559B58-47A4-4835-8A7C-FB8F3BAC84AA

Q35207771-2D5127A8-C9A7-4C02-B62D-14BD1A9D3FDE

Q35207771-3EBDE3C9-ABEE-444C-87DE-3BAD389F52D0

Q35207771-448F4D17-0D01-4EDA-865A-086ACEFB1293

Q35207771-4988719C-65EE-49E8-94BC-A0B5E8E3D1DE

P304

Q35207771-19926B3E-4763-4F6E-BA63-A6E879AD3249

P31

Q35207771-9623A8E9-0C37-4D15-8C3A-9C4607065E3F

P356

Q35207771-040F9226-E22C-4580-8D9F-0FA75B740938

P433

Q35207771-E66F2DA1-C643-4B6F-BBFB-487B1E9C6833

P478

Q35207771-53B3F4F9-E1AA-415D-9126-1F9F3C52C2A7

P577

Q35207771-12F50E0C-0D80-44BF-901D-D164023CE17C

P698

Q35207771-87AE673E-98CE-4E10-9571-FECCED77390E

P932

Q35207771-2415BD15-62F2-476C-AA9B-2DE0E633161E

P356

TA.0000000000000341

P1433

The Journal of Trauma and Acute Care Surgery

P1476

Hyperfibrinolysis, physiologic ...... ce to antifibrinolytic therapy

@en

P2093

Angela Sauaia

http://www.w3.org/2001/XMLSchema#string

Anirban Banerjee

http://www.w3.org/2001/XMLSchema#string

Christopher C Silliman

http://www.w3.org/2001/XMLSchema#string

Eduardo Gonzalez

http://www.w3.org/2001/XMLSchema#string

Ernest E Moore

http://www.w3.org/2001/XMLSchema#string

Hunter B Moore

http://www.w3.org/2001/XMLSchema#string

Michael P Chapman

http://www.w3.org/2001/XMLSchema#string

Theresa L Chin

http://www.w3.org/2001/XMLSchema#string

P2860

HOMOTRANSPLANTATION OF THE LIVER IN HUMANS

Aprotinin during coronary-artery bypass grafting and risk of death

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial

Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers

Criteria for empiric treatment of hyperfibrinolysis after trauma.

Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.

A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis

Coagulation during and after orthotopic transplantation of the human liver.

Tranexamic acid in trauma: how should we use it?

Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors.

P304

811-7; discussion 817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TA.0000000000000341

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25051384

http://www.w3.org/2001/XMLSchema#string

P932

4370273

http://www.w3.org/2001/XMLSchema#string